Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
S
Sharon Moe, MD
Primary Investigator
Overview
The purpose of this study is to determine whether the diabetes drug pioglitazone (Actos) is a safe and effective treatment of autosomal dominant polycystic kidney disease when treated in its early stages.
Description
The objective in the proposed studies is to conduct a preliminary evaluation of drug therapy using a low dose of an insulin sensitizing agent, pioglitazone, for the treatment of autosomal dominant polycystic kidney disease (ADPKD), the most common heritable form of kidney disease.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Autosomal Dominant Polycystic Kidney Disease,1308084213
-
Age: Between 18 Years - 55 Years
-
Gender: All
Inclusion Criteria
For female patients, a willingness to use double contraception to avoid pregnancy while in study
In the opinion of the investigator, high likelihood of progressive kidney disease
Exclusion Criteria
Diabetes
Uncontrolled hypertension as determined by the examining physician
History of impaired systolic function by previous ECHO or known ischemic cardiovascular disease
Findings suggestive of a kidney disease other than ADPKD
Systemic illness requiring immunosuppressive or anti-inflammatory agents
Congenital absence of a kidney or history of a total nephrectomy
History of cyst reduction or partial nephrectomy
History of renal cyst aspiration within the previous year
History of bladder cancer, or gross hematuria
Inability to undergo MRI due to implantable devices or foreign objects that preclude MRI
Active renal transplant
Allergy or sensitivity to any of the components of the test materials
Additional Information:For female patients, a willingness to use double contraception to avoid pregnancy while in study
In the opinion of the investigator, high likelihood of progressive kidney disease
Exclusion Criteria
Diabetes
Uncontrolled hypertension as determined by the examining physician
History of impaired systolic function by previous ECHO or known ischemic cardiovascular disease
Findings suggestive of a kidney disease other than ADPKD
Systemic illness requiring immunosuppressive or anti-inflammatory agents
Congenital absence of a kidney or history of a total nephrectomy
History of cyst reduction or partial nephrectomy
History of renal cyst aspiration within the previous year
History of bladder cancer, or gross hematuria
Inability to undergo MRI due to implantable devices or foreign objects that preclude MRI
Active renal transplant
Allergy or sensitivity to any of the components of the test materials
Participants will be compensated for their participation.
Updated on
19 Apr 2024.
Study ID: 1308084213
